TORONTO, Jan. 29, 2019 /CNW/ - HLS Therapeutics Inc.
("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical
company specializing in central nervous system and cardiovascular
markets, announces that it has received the conditional approval of
the Toronto Stock Exchange ("TSX") to graduate from the TSX Venture
Exchange to list the Company's common shares on the TSX.
"Graduating to the TSX represents an important milestone for the
Company as we continue to execute on our plan to build, and grow, a
leading Canadian-based North American-focused specialty
pharmaceutical company," said Greg
Gubitz, CEO of HLS. "Our listing on the TSX is expected to
open our story to a broader network of investors, both here in
Canada and abroad, therefore
improving access to capital and enhancing liquidity."
Final approval of the listing is subject to HLS fulfilling
certain standard and customary conditions required by the TSX on or
before April 16, 2019. HLS expects
that it will satisfy all requirements in due course and will issue
further communication upon final approval from the TSX. Upon
completion of these final listing requirements, HLS's common shares
will begin trading on the TSX under the ticker "HLS" and will be
subsequently delisted from the TSX Venture Exchange.
ABOUT HLS THERAPEUTICS INC.
Formed in 2015, HLS is a specialty pharmaceutical company
focused on the acquisition and commercialization of late stage
development, commercial stage promoted and established branded
pharmaceutical products in the North American markets. HLS's focus
is on products targeting the central nervous system and
cardiovascular therapeutic areas. HLS's management team is composed
of seasoned pharmaceutical executives with a strong track record of
success in these therapeutic areas and at managing products in each
of these lifecycle stages.
FORWARD LOOKING INFORMATION
This release includes forward-looking statements regarding
HLS and its business. Such statements are based on the current
expectations and views of future events of HLS's management. In
some cases the forward-looking statements can be identified by
words or phrases such as "may", "will", "expect", "plan",
"anticipate", "intend", "potential", "estimate", "believe" or the
negative of these terms, or other similar expressions intended to
identify forward-looking statements, including, among others,
statements with respect to HLS's pursuit of additional product and
pipeline opportunities in certain therapeutic markets, statements
regarding growth opportunities and expectations regarding financial
performance. The forward-looking events and circumstances discussed
in this release may not occur and could differ materially as a
result of known and unknown risk factors and uncertainties
affecting HLS, including risks relating to the specialty
pharmaceutical industry, risks related to the regulatory approval
process, economic factors and many other factors beyond the control
of HLS. Forward-looking statements and information by their nature
are based on assumptions and involve known and unknown risks,
uncertainties and other factors which may cause HLS's actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance or
achievements expressed or implied by such forward-looking statement
or information. Accordingly, readers should not place undue
reliance on any forward-looking statements or information. A
discussion of the material risks and assumptions associated with
this release can be found in the Company's Annual Information Form
dated October 26, 2018, which has
been filed on SEDAR and can be accessed at www.sedar.com..
Accordingly, readers should not place undue reliance on any
forward-looking statements or information. Except as required by
applicable securities laws, forward-looking statements speak only
as of the date on which they are made and HLS undertakes no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE HLS Therapeutics Inc.